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Introduction
Malignant pleural mesothelioma (MPM) is a highly lethal cancer arising from mesothelial cells of the pleural 
cavity upon occupational exposure to asbestos (1). MPM pathogenesis is associated with the carcinogenic 
effect of asbestos that is directly mutagenic for mesothelial cells. By triggering chronic inflammation, frustrat-
ed phagocytosis by macrophages also contributes to MPM. Once MPM is diagnosed, the median survival 
of patients with MPM is about 5–17 months (2, 3). Despite limitations of asbestos usage in industrialized 
countries, incidence of MPM is nevertheless predicted to peak in the next decade, mainly because of long 
latency periods preceding neoplasia. Currently available treatments are disappointing: the standard chemo-
therapy based on an antifolate (pemetrexed) and a DNA–cross-linking agent (cisplatin) only slightly prolongs 
overall survival (4). Among histological types of MPM (epithelial, sarcomatoid, and biphasic or mixed), the 
sarcomatoid phenotype is particularly associated with a more aggressive progression. Although imperfectly 
understood, onset of MPM correlates with modifications in specific genomic regions corresponding to the 
NF2, TP53, SETD2, and BAP1 genes (5). Among these, loss of BAP1 promotes MPM cell proliferation by 
upregulating enhancer of zeste homolog 2 (EZH2), the H3 lysine 27–specific (H3K27-specific) n-methyltrans-
ferase subunit of the polycomb repressive complex 2 (6). Consistently, proliferation induced by Bap1 deletion 
is rescued by the loss of EZH2. Based on this concept, S-adenosyl-l-methionine–competitive pharmacological 
The roles of macrophages in orchestrating innate immunity through phagocytosis and T 
lymphocyte activation have been extensively investigated. Much less understood is the unexpected 
role of macrophages in direct tumor regression. Tumoricidal macrophages can indeed manifest 
cancer immunoediting activity in the absence of adaptive immunity. We investigated direct 
macrophage cytotoxicity in malignant pleural mesothelioma, a lethal cancer that develops from 
mesothelial cells of the pleural cavity after occupational asbestos exposure. In particular, we 
analyzed the cytotoxic activity of mouse RAW264.7 macrophages upon cell-cell contact with 
autologous AB1/AB12 mesothelioma cells. We show that macrophages killed mesothelioma 
cells by oxeiptosis via a mechanism involving enhancer of zeste homolog 2 (EZH2), a histone 
H3 lysine 27–specific (H3K27-specific) methyltransferase of the polycomb repressive complex 
2 (PRC2). A selective inhibitor of EZH2 indeed impaired RAW264.7-directed cytotoxicity and 
concomitantly stimulated the PD-1 immune checkpoint. In the immunocompetent BALB/c model, 
RAW264.7 macrophages pretreated with the EZH2 inhibitor failed to control tumor growth of AB1 
and AB12 mesothelioma cells. Blockade of PD-1 engagement restored macrophage-dependent 
antitumor activity. We conclude that macrophages can be directly cytotoxic for mesothelioma 
cells independent of phagocytosis. Inhibition of the PRC2 EZH2 methyltransferase reduces this 
activity because of PD-1 overexpression. Combination of PD-1 blockade and EZH2 inhibition restores 
macrophage cytotoxicity.
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inhibitors of EZH2 recently entered clinical trials of advanced solid tumors, B cell lymphomas, and multiple 
myeloma (https://clinicaltrials.gov: NCT01897571, NCT02395601, NCT02082977, NCT02860286). The pre-
liminary results of these trials seem promising although still unsatisfactory (7). In relapsed or refractory MPM 
with BAP1 inactivation, a significant proportion of patients achieved disease control in response to tazemeto-
stat monotherapy (i.e., 25% at 24 weeks) (7).
A major issue is that pharmacological inhibitors of  EZH2 not only target the tumor cells, but also 
indirectly affect the tumor microenvironment. More specifically, macrophages are major modulators of  
the local antitumor immune response (8, 9). In fact, macrophages show a wide range of  activation states 
between the 2 M1 and M2 extremes (i.e., classically and alternatively activated macrophages), depending 
on stimuli produced in their microenvironment (10). M1 macrophages are induced by TLR-4 agonists 
released by MPM cells (e.g., HMGB1, HSP90) and proinflammatory cytokines (e.g., IL-12, IFN-γ) and 
support antitumor immunity. In contrast, M2 and tumor-associated macrophages are induced by anti-
inflammatory mediators (e.g., IL-10, PGE-2, TGF-β) and promote tumor progression and resistance to 
therapies (11). Adequate modulation of  intratumor macrophages is necessary to support development of  
cytotoxic T cells’ responses toward tumor-associated antigens. Much less understood is the unexpected 
role of  macrophages in direct tumor regression (12). Tumoricidal macrophages can indeed manifest cancer 
immunoediting activity in the absence of  adaptive immunity (13). This concept of  cancer immunoediting 
integrates the dual role of  the immune system: host protective (e.g., suppression of  tumor growth) and 
tumor promoting (selection of  fitter tumor cells within their microenvironment) (14).
In this report, we address the mechanism of  cancer immunoediting in the context of  a syngeneic model 
that includes MPM tumor cells (AB1 and AB12), RAW264.7 macrophages, and BALB/c mice. We demon-
strate that macrophages are directly cytotoxic by cell-to-cell contact with MPM cells. Besides ROS and 
peroxynitrites, EZH2 methyltransferase activity is primarily required for macrophage cytotoxicity toward 
syngeneic MPM cells. In 2 BALB/c models injected with sarcomatoid (AB1) and biphasic (AB12) cells, 
EZH2 inhibition reverts RAW264.7 macrophage–directed tumor regression. Inhibition of  macrophage 
cytotoxicity by EZH2 involves engagement of  the PD-1 immune checkpoint.
Results
Conditioned supernatant from RAW264.7 macrophages is cytotoxic to AB1 mesothelioma cells. Besides their phago-
cytic activity, activated macrophages also secrete metabolites that are cytotoxic for tumor cells (15). To 
address this mechanism in MPM, we stimulated RAW264.7 macrophages with mock agent or LPS for 24 
hours, added their culture supernatant (SN) to murine mesothelioma AB1 cells, and measured apoptosis 48 
hours later according to the experimental setting of  Figure 1A. The representative dot plot shows that, in 
these conditions, AB1 cells stained positive for propidium iodide and annexin V labeling, indicating onset 
of  apoptosis (compare without SN, SN-mock, and SN-LPS in Figure 1B). As a control, the tyrosine kinase 
inhibitor lapatinib induced similar rates of  apoptosis. Compilation of  8 independent experiments validated 
this conclusion statistically (Figure 1C). In this model, RAW264.7 cells thus secrete metabolites that are 
cytotoxic to AB1 MPM cells.
To identify the mechanisms involved in indirect cytotoxicity, we used a pharmacological approach 
to interfere with NOS, ROS, and peroxynitrites. Synthesis of  NO by NOS can be inhibited by an ana-
log of  l-arginine, L-NMMA. ROS are reduced by apocynin that inhibits the intracellular translocation 
of  2 critical cytosolic components of  the NADPH oxidase complex. Dose response analyses indicated 
that 1 mM L-NMMA and 300 μM apocynin did not affect viability of  RAW264.7 and AB1 cells (Sup-
plemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.128474DS1). L-NMMA at 1 mM significantly reduced the concentration of  nitrites in the SN in 
the presence or absence of  LPS (Figure 1D). In these conditions, the cytotoxic activity of  RAW264.7-con-
ditioned SN was, however, only marginally affected (Figure 1C). In contrast, inhibition of  ROS with a 
subtoxic dose of  300 μM apocynin (Figure 1E) significantly reduced SN cytotoxicity in the presence of  
LPS (Figure 1C). Similarly, peroxynitrite decomposition by FeTTPS reduced apoptosis of  AB1 cells in the 
presence of  LPS (Figure 1C).
These observations thus indicate that ROS and peroxynitrites, but not NO, modulate indirect cytotox-
icity of  RAW264.7-conditioned SN toward AB1 cells. Because peroxynitrites are formed by the association 
of  NO and superoxide, it appears that ROS are key mediators of  cytotoxicity.
RAW264.7 macrophages are directly cytotoxic for mesothelioma cells by cell-to-cell contact. We next evaluated 
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Figure 1. Cytotoxicity of RAW264.7-conditioned SN toward AB1 mesothelioma cells. (A) Experimental design of RAW264.7 macrophages treat-
ed with mock agent, NG-monomethyl-l-arginine (L-NMMA), or apocynin for 24 hours in a 24-well plate. After stimulation with LPS for 24 hours, 
the cell culture SN was collected and clarified by centrifugation for 6 minutes at 500 g. AB1 cells were cultivated for 48 hours in 25% macro-
phage-conditioned SN mixed with 75% complete RPMI 1640 containing 10% FCS and 1% penicillin and streptavidin. The peroxynitrite scavenger 
[5,10,15,20-tetrakis(4-sulfonatophenyl)-prophyrinato iron (III) chloride; FeTTPS] was directly added to the culture medium. (B) Apoptosis was 
evaluated after labeling with annexin V-FITC (Becton Dickinson) and propidium iodide (PI, MilliporeSigma). Data were collected with an FACSAria 
cytometer and analyzed by the FACSDiva software. Treatment with a tyrosine kinase inhibitor (10 μM of lapatinib) for 24 hours was used as a positive 
control. Both PI–annexin V+ and PI+annexin V+ cells were considered to have undergone apoptosis. (C) Apoptotic rates of AB1 cells were quantified by 
flow cytometry after labeling with annexin V-FITC. Mean values and standard deviations were deduced from 8 independent experiments. (D) Nitrites 
(μM) were quantified in the cell SN using the Griess reaction assay. (E) Intracellular ROS were measured by flow cytometry using the cell-permeant 2′, 
7′-dichlorodihydrofluorescein diacetate (H2DCFDA) probe. Each bar represents the mean ± SEM from 8 independent experiments performed in tripli-
cate. Statistical significance was evaluated using 1-way ANOVA followed by Tukey’s multiple-comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001. 
MFI, mean fluorescence intensity.
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the ability of  RAW264.7 to kill AB1 mesothelioma cells upon direct contact (Figure 2A). In this system, 
AB1 cells were not phagocytosed but rather directly killed by LPS-stimulated RAW264.7 macrophages 
(Figure 2B and Supplemental Videos 1 and 2). Morphological changes associated with AB1 cell death were 
confirmed by permeability to propidium iodide (Supplemental Figure 2). Confocal microscopy showed 
that tyrosine nitration to 3-nitrotyrosine, a central modification associated with oxidative stress, occurred 
in LPS-stimulated, F4/80–labeled RAW264.7 macrophages (N-Tyr in Figure 2C). Upon contact with 
RAW264.7, AB1 cells also stained positive for 3-nitrotyrosine, revealing macrophage-associated oxidative 
stress in membrane and cytosolic compartments. Pretreatment of  macrophages with L-NMMA only mod-
estly affected AB1 apoptosis in the presence or absence of  LPS (Figure 2D). In contrast, inhibition of  
ROS with apocynin impaired the cytotoxicity of  RAW264.7 toward AB1 cells (Figure 2D). To investigate 
whether ROS-mediated cell death of  AB1 cells involved oxeiptosis, phosphoglycerate mutase 5 (PGAM5) 
expression was silenced by RNA interference using lentiviral transduction of  2 shRNAs (shPGAM#2 and 
shPGAM#5). The levels of  PGAM5 transcripts were reduced in AB1 transduced with the PGAM5 shR-
NAs compared with the scramble control (Figure 2E). When PGAM5 was knocked down, RAW264.7 
cell–induced apoptosis of  AB1 cells was significantly reduced (Figure 2F).
We conclude that RAW264.7 macrophages are directly cytotoxic to AB1 macrophages through a 
PGAM5-dependent mechanism that involves oxidative stress.
Pharmacological inhibition of  EZH2 reduces direct and indirect cytotoxicity of  RAW264.7 macrophages. Emerg-
ing evidence indicates an important role for epigenetic mechanisms in modulating and transmitting signals 
during macrophage differentiation and polarization (16). Because epigenetic marks such as H3K27me3 
orchestrate the magnitude and specificity of  gene expression and determine macrophage phenotype, we 
evaluated the effect of  an inhibitor of  EZH2 on macrophage cytotoxicity.
RAW264.7 macrophages were incubated with a subtoxic dose of  EPZ5687 (10 μM), an EZH2 inhibitor 
(EPZ) for 48 hours and then treated with LPS for an additional day (see Supplemental Figure 1 for dose 
response of  RAW264.7 to EPZ). At this concentration, EPZ did not affect phagocytosis by RAW267.4 
(Supplemental Figure 3). As expected, H3K27me3 labeling was reduced by EPZ in confocal microscopy 
experiments (illustrated in Figure 3A and normalized to Draq5 nuclear staining in Figure 3B). Consistently, 
flow cytometry confirmed a reduction of  H3K27me3 fluorescence normalized to total histone H3 (Figure 
3C). EPZ only modestly increased the concentrations of  ROS and nitrites (Figure 3, D and E). In these 
experimental conditions, EPZ significantly inhibited apoptosis induced by RAW264.7-conditioned SNs 
(Figure 3F) and direct cytotoxicity (Figure 3G). Time-lapse microscopy revealed that CFSE-labeled mac-
rophages induced annexin V staining of  AB1 cells after to cell-to-cell contact, indicating onset of  apoptosis 
(Figure 3H and Supplemental Video 3). Kinetic analysis confirmed that cocultivation of  AB1 cells with 
RAW264.7 increased the number of  annexin V+ AB1 cells (compare black and gray lines in Figure 3I). 
Preincubation of  macrophages further increased apoptosis (blue line). In the presence of  EPZ, the ability 
of  RAW264.7 macrophages to kill AB1 cells was drastically affected (red and green lines in Figure 3I). 
To further support the involvement of  EZH2, RAW264.7 macrophages were transduced with lentiviruses 
encoding shRNAs. Apoptosis of  AB1 cells was significantly reduced when EZH2 was knocked down in 
RAW264.7 macrophages compared with the scramble control (Supplemental Figure 4).
Together, these data thus show that inhibition of  EZH2 reduces direct and indirect cytotoxicity of  
RAW264.7 macrophages.
Targeting EZH2 abrogates tumor clearance by RAW264.7 macrophages. Because AB1 and RAW264.7 
cells were generated on a BALB/c genetic background, we were able to investigate mesothelioma pro-
gression in a murine syngeneic system. We used 2 immunocompetent models based on AB1 and AB12 
cells pertaining to different subtypes (sarcomatoid and biphasic, respectively) that closely mimic devel-
opment of  human mesothelioma (17). To parallel in vitro studies (Figure 3), RAW264.7 macrophages 
were cultivated in the presence or absence of  EPZ and stimulated or not with LPS. After 3 washes, 
RAW264.7 cells were inoculated subcutaneously (SC) into the flanks of  BALB/c mice with AB1 or 
AB12 cells at a 1:3 ratio (Figure 4A). Both mesothelioma cell lines rapidly induced tumor growth (Fig-
ure 4, B, D, F, and H) and affected mice viability (Figure 4, C, E, G, and I). RAW264.7 macrophages 
were not tumorigenic but almost completely abrogated tumor development of  AB1 or AB12 cells (Fig-
ure 4, B–D). This mechanism was nevertheless ineffective when RAW264.7 macrophages were pretreat-
ed with EPZ in culture before inoculation. A similar trend was observed in AB1 sarcomatoid tumors 
coinjected with RAW264.7 macrophages conditioned in vitro with LPS (compare blue and green lines 
5insight.jci.org   https://doi.org/10.1172/jci.insight.128474
R E S E A R C H  A R T I C L E
Figure 2. Direct cytotoxicity of RAW264.7 macrophages upon cell-to-cell contact with syngeneic mesothelioma AB1 cells. (A) Experimental 
design. RAW264.7 macrophages were treated with L-NMMA or apocynin for 24 hours and then further cultivated in the presence or absence of 
LPS for 24 hours. After 3 washes in PBS, RAW264.7 macrophages were cocultivated with AB1 cells at a 10:1 ratio for 48 hours. (B) AB1 cells and 
CFSE-labeled RAW264.7 macrophages were monitored by time-lapse microscopy using an LSM 510 (Zeiss) equipped with an environmental 
chamber maintained at 37°C in a humidified 5% CO2 atmosphere. (C) Cells were fixed, permeabilized, and stained for F4/80 (shown in green) and 
nitrosylated tyrosine (N-Tyr; shown in blue). Images were acquired using a Zeiss LSM 510 confocal microscope equipped with a ×63-1.4 oil immer-
sion objective. (D) Apoptotic rates of AB1 cells were determined by flow cytometry after staining with the annexin V-FITC kit (Becton Dickinson). 
Each bar represents the mean ± SD from 8 independent experiments performed in triplicate. (E) AB1 cells were transduced by lentivectors encoding 
PGAM5 shRNAs (#2 and #5) or a scramble control. The levels of PGAM5 transcripts were measured by reverse transcription quantitative PCR. (F) 
RAW264.7-induced apoptosis of shRNA-transduced AB1 cells was measured as described in D. Each bar represents the mean ± SD from 6 indepen-
dent experiments. Statistical significance was evaluated using 1-way ANOVA followed by Tukey’s multiple-comparisons test. *P < 0.05; **P < 0.01; 
***P < 0.001.
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in Figure 4F). Pretreatment of  RAW264.7 macrophages with LPS abolished their ability to control 
tumor growth in biphasic AB12 cells (Figure 4H).
Hematoxylin and eosin counterstaining revealed infiltration of  immune cells, such as macrophages, 
granulocytes, and lymphocytes, in RAW264.7+ AB1 tumors (Figure 5A). When RAW264.7 macrophages 
were coinjected with AB1 cells, infiltration of  CD3+ cells increased (Supplemental Figure 5A). In contrast, 
AB1 tumors of  similar size displayed a different pattern of  fusiform cells. Tumors were analyzed by con-
focal microscopy using macrophage-specific monoclonal F4/80 and antibodies against cleaved caspase-3. 
Figure 5B illustrates pseudopodia from macrophages interacting with apoptotic neighboring mesothelioma 
cells. Quantification of  cleaved caspase-3–associated fluorescence revealed that apoptosis was significantly 
reduced in AB1 tumors coinjected with EPZ-treated RAW264.7 cells (Figure 5C).
We conclude that (a) RAW264.7 cells efficiently control tumor development in 2 immunocompetent 
models of  murine mesothelioma and (b) EZH2 is required for macrophage cytotoxicity.
Inhibition of  EZH2 stimulates PD-1 expression on RAW264.7 while PD-1 blockade restores macrophage cyto-
toxicity. Because PD-1 has been associated with inhibition of  phagocytic potency (18), we hypothe-
sized that a similar mechanism also operated in macrophage-directed cytotoxicity. PD-1 expression 
in tumor biopsies increased when AB1 cells were coinjected with RAW264.7 macrophages compared 
with AB1 alone (Supplemental Figure 5B). When RAW264.7 cells were pretreated with LPS or EPZ, 
PD-1 expression was further stimulated in tumors. Flow cytometry demonstrated that EPZ enhanced 
PD-1 expression in the presence and absence of  LPS (Figure 6, A and B). In the presence of  EPZ, 
PD-1 expression increased at both the protein and RNA levels and was associated with a reduction 
of  H3K27me3 at the PD-1 promoter (Supplemental Figure 6). Time-lapse analysis showed that PD-1 
(stained in red on Figure 6C) localized at the synapse between RAW264.7 and AB1 (arrows at T0 + 2h 
in Figure 6C). Engagement of  PD-1 between EPZ-conditioned macrophages and AB1 cells resulted in 
killing inhibition (Supplemental Video 4). Blockade with an anti–PD-1 antibody but not with an isotype 
control restored apoptosis of  AB1 cells (Figure 6D). Blockade of  the PD-1 ligand (PD-L1) resulted in 
an intermediate effect compared with the isotype control (Supplemental Figure 7). In the mouse model, 
macrophages pretreated with EPZ and anti–PD-1 antibody efficiently controlled AB1 and AB12 tumor 
growth (Figure 6, E and F, and Supplemental Figure 8).
Together, these data demonstrate that EPZ stimulates expression of  the PD-1 checkpoint inhibitor 
on RAW264.7 macrophages. Blockade of  PD-1 restores the antitumor activity of  EPZ-treated macro-
phages toward AB1 cells.
Discussion
In MPM, macrophages are massively recruited into the pleura and orchestrate an early inflammatory response 
toward tumor cells (9, 19, 20). This antitumor immunity is initiated by a series of  features that distinguish 
normal from mesothelioma cells (e.g., altered expression of  genes involved in cell metabolism and apoptosis). 
Tumor cells also release danger-associated molecular patterns that are detected by the innate immune system 
(21, 22). Mesothelioma cells further secrete endogenous ligands of  TLR-4, such as HMGB-1, tenascin-C, 
and HSP-70/90 (23–28). Upon initiation, macrophages phagocytose and degrade cancer cells (29, 30). In 
Figure 3. Effect of EZH2 inhibition by EPZ on RAW264.7-mediated killing of AB1 cells. RAW264.7 macrophages were incubated with the EZH2 
inhibitor (10 μM EPZ5687) for 48 hours and treated or not with LPS for 24 hours. (A) RAW264.7 macrophages were labeled with an anti-H3K27me3 
antibody, stained with Draq5, and analyzed by confocal microscopy. Magnification 40×. (B) The rMFI corresponds to the ratio of fluorescence intensities 
associated with H3K27me3 and Draq5. (C) RAW264.7 macrophages were fluorescently labeled with antibodies against pan-Histone 3 or H3K27me3 and 
analyzed by flow cytometry using a FACSaria flow cytometer (Becton Dickinson). The rMFI represents the ratio of fluorescence intensities associated 
with H3K27me3 and pan-H3. (D) Intracellular ROS were measured by flow cytometry using the cell-permeant H2DCFDA probe. MFI, mean fluorescence 
intensity. (E) Nitrites (in μM) in the cell SNs were quantified by the Griess reaction assay. (F) RAW264.7 macrophage–conditioned SNs were added 
to AB1 cell cultures as described in Figure 1A. Apoptosis was determined by flow cytometry after labeling with annexin V-FITC. (G) CFSE-labeled 
RAW264.7 macrophages were cocultivated for 48 hours with AB1 cells at a 10:1 ratio. Apoptotic rates of CFSE– AB1 cells were determined by flow 
cytometry after staining with the annexin V-FITC kit (Becton Dickinson). Each bar represents the mean ± SD. Statistical significance was evaluated 
using the paired Student’s t test (B and C) and 1-way ANOVA followed by Tukey’s multiple-comparisons test (D–G). *P < 0.05; **P < 0.01; ***P < 0.001. 
(H) CFSE-labeled RAW264.7 macrophages were cocultivated for 24 hours with AB1 cells at a 1:1 ratio in the presence of annexin V-APC (red fluores-
cence). The cells were monitored by the IncuCyte S3 Live-Cell imaging system (Essen Bioscience) placed in an incubator maintained at 37°C in a humidi-
fied 5% CO2 atmosphere. (I) RAW264.7 macrophages pretreated with EPZ and/or LPS were cocultured with CFSE-labeled AB1 cells. The number of 
CFSE+ (AB1) annexin V+ events was determined every 10 minutes for 24 hours using the IncuCyte S3 Live-Cell imaging system. Each curve is the average 
of 5 independent experiments performed in triplicate.
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this report, we investigated a different mechanism of macrophage-dependent anticancer activity that does not 
involve prior phagocytosis. As CD8+ cytotoxic T cells, macrophages are indeed well armed to directly destroy 
tumor cells (e.g., reactive oxygen/nitrogen species [RONS], FasR/FasL, TRAIL-R/TRAIL-L, TNF-R/
TNF-α). Using 2 mesothelioma cell lines, we demonstrate here that autologous RAW264.7 macrophages 
direct cytolytic activity before phagocytosis (Figure 2). This activity primarily requires ROS as revealed by the 
Figure 4. Effect of EPZ on RAW264.7-mediated inhibition of AB1 tumor growth. (A) RAW264.7 macrophages were cultured 
with the EZH2 inhibitor (10 μM EPZ5687) for 24 hours and stimulated with LPS for an additional day. After 3 washes, 
RAW264.7 cells were coimplanted subcutaneously (SC) in BALB/c mice with 2 × 106 AB1 or AB12 cells at a 1:3 ratio. In B, D, 
F, and H, tumor volumes (in mm3) were calculated weekly using the following formula: 4/3 × π × (diameter/2)3. C, E, G, and I 
represent the corresponding survival curves. Groups of at least 6 mice were tested in each experimental condition. All data 
are plotted as mean ± SEM (n = 6). Statistical significance was evaluated using 2-way ANOVA with Bonferroni’s post test (B, 
D, F, and H) and log-rank χ2 test (survival curves). *P < 0.05; **P < 0.01; ***P < 0.001.
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use of  apocynin, a pharmacological inhibitor of  the superoxide radical (O2
–) that interferes with intracellular 
translocation of  the cytosolic component (p47-phox and p67-phox) of  NADPH oxidase (31). In contrast, 
inhibition of  NOS by L-NMMA (32) has no effect in our experimental settings likely because NO recombines 
with the short-lived (O2
–) radical to generate peroxynitrite anion (ONOO–) (33, 34). Consistently, neutraliza-
tion of  peroxynitrites with FeTTPS quenched the cytotoxic potency of  LPS-primed, RAW264.7-conditioned 
SN (Figure 1C). Note that the involvement of  peroxynitrites in direct cytotoxicity could not be determined 
because FeTTPS excessively reduced RAW264.7 metabolic activity (Supplemental Figure 1). Furthermore, 
covalent association of  NO2− with the aromatic ring of  tyrosine (3-nitrotyrosination) appeared in AB1 meso-
Figure 5. Immunohistochemistry of AB1 mesothelioma tumors. (A) Histochemical analyses of tumors from BALB/c 
mice inoculated with AB1 tumor cells and RAW264.7 macrophages differentiated in the presence or absence of EPZ 
and/or LPS. Sections from tumors with similar volumes were stained with hematoxylin and eosin (original magni-
fication, ×20). (B) Representative immunohistochemistry micrographs of apoptotic cells and F4/80+ macrophages. 
Apoptotic cells were labeled with an antibody directed against cleaved caspase-3 (active) and an Alexa Fluor 546 con-
jugate (in red). Infiltrating macrophages were identified by F4/80 and anti-IgG Alexa Fluor 488 antibodies (in green). 
Cell nuclei were stained with DAPI (in blue). The higher magnification (original magnification, ×40) reveals macrophage 
pseudopodia interacting with an apoptotic tumor cell (white arrows). (C) The cleaved caspase-3 fluorescence intensity 
(FI) was quantified from 25 images (3 × 3 segmentation at original magnification ×40) by using ImageJ and FSX100. 
Each bar represents the mean ± SD. *P < 0.05, evaluated using the 2-tailed Mann-Whitney U test.
 
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.128474
R E S E A R C H  A R T I C L E
thelioma cells upon contact with RAW264.7 (Figure 2C). 3-nitrotyrosination also occurred in the activated 
RAW264.7 as well as in neighboring cells (data not shown), further supporting the role of  RONS and per-
oxynitrites in macrophage-mediated cell killing. RAW264.7 macrophages are thus similar to dendritic cells 
that also use peroxynitrite to exert their tumoricidal activity upon activation by LPS (35, 36). ROS and per-
oxynitrites induce oxeiptosis via the Kelch-like ECH-associated protein 1/nuclear factor erythroid 2–related 
factor 2 (Keap1/Nrf2) pathway (37). This mechanism is involved in cytoprotective response to endogenous 
and exogenous ROS. Nrf2 is a transcription factor that induces expression of  antioxidant enzymes, such as 
NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, glutamate-cysteine ligase, and glutathione-S-trans-
ferases. Keap1 binds Nrf2 and induces its ubiquitin-dependent degradation. Under oxidative stress, Keap1 is 
Figure 6. Effect of EPZ on PD-1 expression and activity of anti–PD-1 blockade in AB1/RAW264.7 cocultures. (A) RAW264.7 macrophages were cultured 
in the presence of LPS and/or EPZ as described in Figure 3. After labeling with an anti–mouse PD-1 antibody, fluorescence emission was analyzed by flow 
cytometry using a BD FACSAria. Representative dot plots of FSC-H (x axis) and percentage of PD-1 cells (y axis) are shown. (B) Percentages of RAW264.7 
macrophages expressing PD-1 were deduced from 4 independent experiments. Each bar represents the mean ± SD. **P < 0.01, and ***P < 0.001, calcu-
lated using 1-way ANOVA followed by Tukey’s multiple-comparisons test. (C) Time-lapse analysis of CFSE-labeled AB1 cells cocultured with RAW264.7 
macrophages for 24 hours at a 1:1 ratio in the presence of PE/Cy7–conjugated anti–mouse PD-1 antibody (red). (D) RAW264.7 macrophages were incubated 
with anti–PD-1 antibody (10 μg/mL; InVivoMAb, BioXcell) or rat IgG2a isotype control for 6 hours and then cocultivated with CFSE-labeled AB1 cells in the 
presence of annexin V-APC. The cells were monitored by the IncuCyte S3 Live-Cell imaging system (Essen Bioscience) placed in an incubator maintained 
at 37°C in a humidified 5% CO2 atmosphere. The number of annexin V
+ AB1 cells (percentage) was quantified every 10 minutes for 24 hours. Statistical sig-
nificance was evaluated using 2-way ANOVA with Bonferroni’s post test. ***P < 0.001. (E) RAW264.7 macrophages were cultured with the EZH2 inhibitor 
(10 μM EPZ5687) for 24 hours and with anti–PD-1 antibody (10 μg/mL; InVivoMAb, BioXcell) or Rat IgG2a isotype control (10 μg/mL, BD) for 6 hours before 
inoculation. After 3 washes, RAW264.7 macrophages were coimplanted SC into BALB/c mice with 2 × 106 AB1 or AB12 cells at a 1:3 ratio. Tumor volumes 
(in mm3) were calculated weekly using the following formula: 4/3 × π × (diameter/2)3. (F) The corresponding survival curve for E. Groups of at least 6 mice 
were tested in each experimental condition. All data are plotted as mean ± SEM (n = 6). Statistical significance was evaluated using 2-way ANOVA with 
Bonferroni’s post test (E) and log-rank χ2 test (F). *P < 0.05; **P < 0.01; ***P < 0.001.
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inactivated by oxidation of  cysteine residues, causing Nrf2 accumulation in cells. PGAM5 is pivotal to medi-
ate Keap1-dependent cells’ death in response to ROS. Oxidized Keap1 releases PGAM5 to induce caspase-in-
dependent cell death. RNA interference data (Figure 2F) show that RAW264.7 macrophages induced AB1 
cell death in a PGAM5-dependent manner.
Besides RONS and peroxynitrites, RAW264.7 cytotoxic activity against AB1/AB12 cells also requires 
EZH2 as revealed by the pharmacological inhibitor EPZ5687. Our preliminary results further show that 
the cytotoxicity of  human macrophages pulsed with pleural effusion from MPM patients was also inhibited 
by an inhibitor of  EZH2 (data not shown). Furthermore, we have also obtained evidence that macrophages 
are cytotoxic in spheroid cell culture systems of  RAW264.7 and AB1/AB12 cells (data not shown).
Evidence obtained in cell culture (Figure 3) was further validated by 2 autologous mouse models of  
mesothelioma (Figures 4 And 5). Tumor growth of  sarcomatoid (AB1) and biphasic (AB12) cells was 
abrogated by coinjection of  RAW264.7 macrophages but restored by pretreatment with the EZH2 inhib-
itor. Because the inhibitor is washed out before macrophage inoculation, this experimental setting thus 
investigates RAW264.7 cytotoxicity rather than direct antitumor activity of  EPZ. Pretreatment with LPS 
abolished the capacity of  RAW264.7 cells to efficiently control AB1/AB12 tumor growth (Figure 4, F–I) 
perhaps after LPS-induced inflammation or, as indicated by Supplemental Videos 1 and 4, after macro-
phage apoptosis or induction of  endotoxin tolerance (18, 38–42). In fact, the macrophage response to 
LPS depended on the dose and the duration of  stimulation. The chronic or repeated exposure to TLR-4 
agonists led to macrophage endotoxin tolerance or macrophage exhaustion. Stimulation with LPS aug-
mented PD-1 mRNA and protein levels in RAW264.7 macrophages (data not shown). Furthermore, the 
number of  PD-1+ cells increased upon LPS pretreatment of  RAW264.7 cells (Supplemental Figure 5B). 
Taken together, these observations suggest that LPS-primed RAW264.7 macrophages show an exhausted 
phenotype. Figure 6 shows that AB1 mesothelioma cells were able to escape killing by engaging the PD-1 
checkpoint on RAW264.7 macrophages.
This conclusion is of  paramount importance for clinical trials that currently target EZH2 in differ-
ent cancers with pharmacological inhibitors, such as tazemetostat. Indeed, EZH2 inhibitors are being 
evaluated in advanced solid tumors, B cell lymphomas, and multiple myeloma (https://clinicaltrials.gov: 
NCT01897571, NCT02395601, NCT02082977, NCT02860286). The H3K27me3 epigenetic mark cata-
lyzed by EZH2 is a repressive marker leading to aberrant gene expression during malignant transformation 
(43). Silenced genes exhibit decreased chromatin accessibility and diminished recruitment of  transcrip-
tion factors, such as p65. Inhibition of  EZH2 by RNA interference decreases tumorigenicity of  malignant 
mesothelioma cells (43). Besides this antitumor activity, our report indicates that the EZH2 methyltrans-
ferase exerted an important role in modulating and transmitting signals during macrophage differentiation 
or polarization. In MPM mouse models (Figures 4 And 5), EZH2 was even a limiting factor that was 
required for antitumor activity associated with direct macrophage cytotoxicity. The EZH2 EPZ inhibitor 
only modestly affected RONS (Figure 3, D and E) but stimulated PD-1 expression in macrophages (Figure 
6). Besides the involvement of  PD-1 in phagocytosis (18), engagement of  this checkpoint inhibitor may 
therefore also explain the inability of  macrophages to exert cell-to-cell direct cytotoxicity.
In summary (Figure 7), we have shown that RAW264.7 macrophages are cytotoxic to AB1 cells by 
direct cell-to-cell contact via oxeiptosis. In the absence of  prior phagocytosis, RAW264.7 macrophages 
are thus directly cytotoxic to mesothelioma cells. In autologous mouse models, RAW264.7 macrophages 
impair tumor growth of  AB1/AB12 mesothelioma cells. This activity is abrogated by an inhibitor of  
EZH2 that stimulates expression of  PD-1 (Figure 7). This conclusion justifies the combination of  immune 
checkpoint and EZH2 inhibitors in clinical trials in mesothelioma as well as in other solid tumors (e.g., 
NCT03337698). Considering the complex interactions between EZH2 inhibitors, adaptive resistance to 
tumor immunotherapy, and macrophage direct cytotoxicity (44), understanding the molecular mechanisms 
involved should be considered to design new therapeutic approaches.
Methods
Cell culture. RAW264.7 (ATCC, TIB-71), murine monocytic cells isolated from BALB/c mice, were maintained 
in DMEM supplemented with 10% heat-inactivated FCS (Lonza), along with penicillin and streptavidin (100 
UI/mL, BioWhittaker). AB1 and AB12 mesothelioma cell lines generated after intraperitoneal injection of  
BALB/c mice with crocidolite asbestos were cultivated in complete RPMI 1640 medium (Lonza) containing 
10% FCS and antibiotics (penicillin and streptomycin). Cell lines were maintained at 37°C in a humidified 
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.128474
R E S E A R C H  A R T I C L E
Figure 7. A model for EZH2-
dependent immunoediting 
of mesothelioma cells by 
autologous macrophages. 
Schematic representation 
of direct and indirect 
cytotoxicities mediated 
by ROS and peroxynitrites 
produced by macrophages. 
Oxidative stress induces 
tyrosine nitration in tumor 
cells, leading to apoptosis and 
phagocytosis by macrophages. 
Inhibition of EZH2 reduces 
direct cytotoxicity exerted 
by macrophages without 
affecting ROS production 
but increases PD-1 
expression. The engagement 
of PD-1 at the synapse 
between macrophages and 
mesothelioma cells impairs 
killing activity of macrophages. 
The combination of an 
EZH2 inhibitor (such as 
tazemetostat) and immune 
checkpoint inhibitor 
that targets PD-1 (e.g., 
pembrolizumab, nivolumab) 
restores immunoediting 
activity of macrophages. 
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5% CO2 air atmosphere. RAW264.7 macrophages were transduced with lentiviral vectors (pLVs) coexpress-
ing GFP and shRNA sequences targeting EZH2 (shRNA#1 5′-TTGAGTACTGTGGGCAATTTA-3′, shR-
NA#3 5′-ACTTGCCCACCTCGGAAATTT-3′) or a scramble sequence (5′-CCTAAGGTTAAGTCGC-
CCTCG-3′) (Vector Builder). AB1 cells were transduced with pLVs coexpressing GFP and shRNA sequences 
targeting PGAM5 (shRNA#2 5′-GCCTGGGATTAAAGTTTAATA-3′, shRNA#5 5′-CTGGAGAAGAC-
GAGTTGACAT-3′) or a scramble sequence (5′-CCTAAGGTTAAGTCGCCCTCG-3′) (Vector Builder). 
The transduced RAW264.7 and AB1 cells were selected during 3 weeks with G418 (1 mg/mL, Roche).
Indirect cytotoxicity assay. RAW264.7 macrophages were grown in a 24-well plate (5 × 104 cells/well) in the 
presence of  apocynin (300 μM, Sigma-Aldrich), L-NMMA (1 mM, Sigma-Aldrich), or EPZ (10 μM, Selleck 
Chemicals) for 48 hours and stimulated by LPS (1 μg/mL, LPS from E. coli 055:B5, Sigma-Aldrich) for 24 
hours. The SNs were collected, centrifuged for 6 minutes at 500 g, and added to AB1 cells in a 24-well plate 
(2 × 104 cells/well) for 48 hours. FeTTPS at 75 μM (Calbiochem) was used as a catalyst for peroxynitrite 
decomposition. To quantify apoptosis, floating and adherent cells were pooled, washed twice with cold PBS, 
resuspended in 100 μL of 1× annexin V buffer (Becton Dickinson), and incubated for 15 minutes with 5 μL 
annexin V-FITC and propidium iodide (1 μg/mL, MilliporeSigma) reagent. Fluorescence emission (filter 
530/30) was analyzed by flow cytometry using BD FACSAria, and data were analyzed with the FACSDiva 
software (Becton Dickinson).
Direct cytotoxicity assay. RAW264.7 macrophages (wild-type or knocked down for EZH2) were culti-
vated in a 24-well plate (5 × 104 cells/well) in the presence or absence of  apocynin, L-NMMA, or EPZ 
for 24 hours and then with LPS for 24 hours. AB1 cells (wild-type or knocked down for PGAM5) were 
labeled with 10 μM CFSE (Abcam) according to the manufacturer’s instructions, washed with complete 
RPMI 1640, and cocultivated for 48 hours at a 1:10 ratio with RAW264.7 macrophages. Cells in coculture 
were recorded by time-lapse microscopy using a Zeiss LSM 510 equipped with an environmental chamber 
maintained at 37°C in a humidified 5% CO2 air atmosphere. Apoptosis of  CFSE
+ AB1 cells was analyzed 
by using the annexin V-APC kit (Becton Dickinson). PD-1 expression on RAW264.7 macrophages was 
revealed with PE/Cy7–conjugated anti–mouse PD-1 antibody (clone RMP1-30, SONY Biotechnology). 
Fluorescence emission was analyzed by flow cytometry using an FACSAria (Becton Dickinson). Ten thou-
sand CFSE+ cells were collected and analyzed with the FACSDiva software.
For time-lapse microscopy, CFSE-labeled RAW264.7 and/or AB1 cells were cocultivated for 24 hours 
at a 1:1 ratio in the presence of  annexin V-APC (Becton Dickinson), propidium iodide (0.5 μM, Milli-
poreSigma), or PE/Cy7–conjugated anti–mouse PD-1 (RMP1-30, SONY Biotechnology). For blocking 
PD-1, RAW264.7 macrophages were incubated with anti–PD-1 antibody (10 μg/mL; clone 29F.1A12; 
InVivoMAb, BioXcell) or rat IgG2a isotype control (10 μg/mL, clone R35-95, BD) for 6 hours before cocul-
tivation with AB1 cells. For blocking PD-L1, RAW264.7 cells were cocultivated with AB1 cells in the 
presence of  anti–PD-L1 antibody (10 μg/mL; clone 10F.9G2; InVivoMAb, BioXcell,) or rat IgG2b isotype 
control (10 μg/mL, clone A95-1, BD). The cells were monitored by the IncuCyte S3 Live-Cell imaging 
system (Essen Bioscience) placed in an incubator maintained at 37°C in a humidified 5% CO2 atmosphere. 
The number of  annexin V+ events on CFSE-labeled AB1 cells was determined every 10 minutes for 24 
hours using the IncuCyte S3 Live-Cell imaging system.
Determination of  ROS. Intracellular ROS production was measured using the cell-permeant H2DCF-
DA probe (Molecular Probes). RAW264.7 macrophages (25 × 103 cells/well of  a 96-well microplate) were 
washed with PBS, incubated with 10 μM of H2DCFDA diluted in serum-free RPMI culture medium for 30 
minutes at 37°C, washed once with PBS, and further maintained in serum-free RPMI for 30 minutes. After 
lysis in PBS with 1% Triton X-100 (v/v) for 10 minutes, 150 μL of  cell lysate was transferred into a black 
96-well microplate (PerkinElmer). Fluorescence emission was determined by using a Victor3V 1420 multila-
bel counter (Perkin Elmer Wallac) with an excitation wavelength at 485 nm and an emission filter at 535 nm.
Quantification of  NO production. The levels of  nitrites (NO2
−) were measured using sulfanilamide and 
n-1-napthylethylenediamine dihydrochloride (Griess reaction assay, Promega). Cell culture SNs were incu-
bated with Griess reagent for 15 minutes in the dark at room temperature. The optical density was measured 
at 546 nm with a Multiskan GO Microplate Spectrophotometer (Thermo Fisher Scientific). The concen-
trations of  nitrites were derived by regression analysis using serial dilutions of  sodium nitrite as a standard.
Analysis of  tyrosine nitrosylation by confocal fluorescence microscopy. RAW264.7 cells were cultivated on 
coverslips (5 × 104 cells/well) in the presence or absence of  LPS for 24 hours. Then, RAW264.7 cells were 
cocultivated with AB1 cells for 48 hours at a 10:1 ratio. Cells were fixed with 4% paraformaldehyde in PBS 
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for 15 minutes, permeabilized using 1% Triton X-100 in PBS for 10 minutes, and blocked in PBS containing 
10% FCS for 10 minutes. After a wash with PBS, cells were incubated for 1 hour at room temperature with 
rat anti–mouse F4/80 (Becton Dickinson, clone T45-2342) and rabbit anti-nitrotyrosine (A-21285, Thermo 
Fisher Scientific) antibodies. Then, cells were stained with Alexa Fluor 488 anti–rat IgG and Alexa Fluor 
647 anti–rabbit IgG (Invitrogen) conjugates. Coverslips were washed and mounted in fluoroshield (Mil-
liporeSigma). Images were acquired with a Zeiss LSM 510 confocal microscope equipped with ×40 and 
×63-1.4 oil immersion objectives (Zeiss).
H3K27me3 immunofluorescence. RAW264.7 macrophages (5 × 104 cells/well of  a 24-well plate) were 
grown on coverslips and treated with EPZ for 48 hours. Then, cells were fixed with 4% paraformaldehyde 
for 15 minutes, permeabilized using 1% Triton X-100 in PBS for 10 minutes, and blocked in PBS containing 
10% FCS for 10 minutes. After a wash with PBS, cells were incubated for 1 hour at room temperature with 
a rabbit polyclonal antibody directed against H3K27me3 (07-449, MilliporeSigma) and an Alexa Fluor 
488 anti–rabbit IgG conjugate (Invitrogen). Cells were stained with Draq5 (Invitrogen) and mounted with 
fluoroshield (MilliporeSigma). Images were acquired with a Zeiss LSM 510 confocal microscope equipped 
with ×40 and ×63-1.4 oil immersion objectives (Zeiss). For flow cytometry analysis, RAW264.7 macro-
phages were fixed with 4% paraformaldehyde for 15 minutes, permeabilized using 1% Triton X-100, and 
blocked in PBS containing 10% FCS for 10 minutes. RAW264.7 macrophages were labeled with a rabbit 
polyclonal antibody directed against pan-H3 (RM188, MilliporeSigma) and mouse IgG3 anti-H3K27me3 
(6002, Abcam) for 1 hour. The cells were washed and incubated with Alexa Fluor 647 anti–rabbit IgG 
and Alexa Fluor 488 anti–mouse IgG (Invitrogen) conjugates. Isotype-matched antibodies were used as 
controls. Fluorescence emission was analyzed by flow cytometry using a BD FACSAria, and data were 
analyzed with the FACSDiva software.
RNA analysis. Total RNA was prepared from whole cells using NucleoSpin RNA Plus Kit (Macherey-Na-
gel) according to the manufacturer’s instructions. After reverse transcription using FastGene Scriptase II cDNA 
Kit (Nippon Genetics), the abundance of transcripts was assessed by real-time qPCR analysis using the Takyon 
SYBR MasterMix (Eurogentec) and gene-specific primer sets: PGAM5 (5′-ATCTGGAGAAGACGAGTT-
GACA-3′; 5′-CCTGTTCCCGACCTAATGGT-3′) and GAPDH (5′-CGGAGTCAACGGATTTGGTCG-
TAT-3′; 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′). Samples were amplified in triplicate on each plate, 
and data were analyzed using LightCycler 480 Software (Roche Diagnostics). The fluorescence intensities were 
quantified with LightCycler 480 Software SW 1.5.1. Normalization was performed using mouse GAPDH as 
an internal control, and relative gene expression was calculated using the comparative 2−ΔΔCt method.
ChIP. ChIP of  the PD-1 promoter using anti-H3K27me3 antibody (07-449, MilliporeSigma) was per-
formed using the iDeal ChIP for histones (Diagenode). Briefly, RAW264.7 cells were cross-linked with 1% 
paraformaldehyde for 10 minutes at room temperature. Chromatin was fragmented by sonication using a 
Bioruptor (Diagenode) to an average length of  200–500 base pairs. Antibody-conjugated beads were then 
added to chromatin samples and incubated overnight at 4°C. Chromatin was eluted from the beads, and 
DNA was purified according to the manufacturer’s instructions. Precipitated DNA was amplified with 
Takyon qPCR SYBR MasterMix (Eurogentec) on a LightCycler 480 thermocycler (Roche Diagnostics) 
and primers specific for regions B (5′-CCACCTCTAGTTGCCTGTTCTC-3′ and 5′-CCTCACCTCCT-
GCTTGTCTCTC-3′) and C (5′-GTGAGACCCACACATCTCATTGC-3′ and 5′-ATTCCCATCCAT-
ACCTTGCTCC-3′) of  the PD-1 promoter (GeneID 18566).
Western blot. Whole-cell lysates were prepared using RIPA buffer (50 mM Tris–HCl at pH 8, 150 mM 
NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, and protease inhibitors). After protein quantifica-
tion (Pierce BCA Protein Assay), 50 μg of  lysate was separated by electrophoresis on SDS-PAGE gels and 
blotted onto nitrocellulose. Membranes were incubated with antibodies against PD-1 (84651, Cell Signaling 
Technology), α-tubulin (clone B5-1-2, MilliporeSigma), or EZH2 (clone D2C9, Cell Signaling Technology), 
then with the appropriate secondary antibodies conjugated with horseradish peroxidase (HRP) (antirabbit 
7074, Cell Signaling Technology; anti–mouse P0260, Dako). After incubation with enhanced luminescence 
(Pierce), protein bands were quantified using ImageJ software (NIH).
Animal experiments. All procedures were approved by the Ethical Review Board (protocol 1564) and 
performed according to the Federation of  Laboratory Animal Science Association (FELASA) guidelines. 
Male wild-type BALB/c mice (5–7 weeks old) from the GIGA mouse facility platform (University of  Liège) 
were inoculated with syngeneic RAW264.7 macrophages and AB1/AB12 mesothelioma cells. RAW264.7 
macrophages were cultured with the EZH2 inhibitor (10 μM EPZ) for 24 hours, then activated with LPS (1 
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.128474
R E S E A R C H  A R T I C L E
μg/mL) for an additional day as indicated in Figure 4A. For blocking PD-1, RAW264.7 macrophages were 
incubated with anti–PD-1 antibody (10 μg/mL; InVivoMAb, BioXcell) or rat IgG2a isotype control (10 μg/
mL, Becton Dickinson) for 6 hours before inoculation. After 3 washes with PBS, macrophages were coim-
planted SC with 2 × 106 AB1 or AB12 cells into the flanks of  BALB/c mice at a 1:3 ratio. Tumor volumes 
were calculated weekly using the following formula: 4/3 × π × (diameter/2)3. Groups of  at least 6 mice 
were tested in each experimental condition.
Immunohistochemistry of  tumors. Tumors from each flank were collected, formalin fixed, and paraffin 
embedded. Sections were cut at 4 μm of  thickness and mounted on microscope slides, dewaxed in xylene 
(MilliporeSigma), and rehydrated in graded ethanol bath (MilliporeSigma). Sections were stained with 
hematoxylin and eosin (MilliporeSigma). For immunofluorescence, slides were preincubated with PBS 
containing 0.5% bovine serum albumin (BSA; MilliporeSigma) for 1 hour to reduce nonspecific back-
ground. After rinsing with PBS with 0.5% BSA, samples were incubated with rat anti–mouse F4/80 (Bec-
ton Dickinson) and rabbit anti–active caspase-3 (Becton Dickinson) primary antibodies for 1 hour at room 
temperature. After washing with PBS, slices were incubated with donkey anti–rat Alexa Fluor 488, chicken 
anti–rabbit Alexa Fluor 546, and DAPI for 30 minutes. Slides were imaged with an Olympus FSX100 
epifluorescence microscope by performing 3 × 3 segmentation at an original magnification of  ×40. The 
cleaved caspase-3 fluorescence was quantified from 25 images by using ImageJ and FSX100 software. For 
immunohistochemistry, slides were stained with anti-CD3 (RM9107-S, Thermo Fisher Scientific) or anti–
PD-1 (84651, Cell Signaling Technology) monoclonal antibodies. After incubation with an HRP conjugate, 
sections were stained with hematoxylin and analyzed by using ImageJ and QuPath software (45).
Statistics. The normal distribution, equal variance, and comparison of  means were calculated using 
GraphPad Prism 5 and Minitab 16 (University of  Liege) software. Means within a data set were compared 
by 1-way ANOVA followed by Tukey’s multiple-comparisons test. Parametric paired 2-tailed Student’s t 
test was used to determine the difference between 2 paired distributions. Statistical significance between 
2 non-Gaussian distributions was calculated by using the 2-tailed Mann-Whitney U test. The analysis of  
tumor growth was performed using 2-way ANOVA and Bonferroni’s post tests. Survival curves were com-
pared by using log-rank test (χ2). For immunohistochemistry, statistical analysis was performed using non-
parametric Friedman’s test followed by Dunn’s multiple-comparisons test. Data were considered statistical-
ly significant (*), very statistically significant (**), and highly statistically significant (***) at P < 0.05, P < 
0.01, and P < 0.001, respectively.
Study approval. All procedures were approved by the ethical review board of  the University Hospital of  
Liege (protocol 1564) and performed according to the FELASA guidelines.
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